Growth of 40% per annum continues for AFT Pharmaceuticals in the Australasian market (Australia and NZ) with sales for this year due to break $22 million per annum.
Global
AFT Group Sales Growth continues at +40%
Join our team
We’re always looking for talented people, please have a look at the careers we currently have available.
Similar News
Stay informed with our other news articles
May 26, 2025
AFT and Hikma extend US Maxigesic Cooperation
AFT Pharmaceuticals (NZX:AFT, ASX:AFP) today announces it has extended its US Maxigesic® licensing agreement with Hikma Pharmaceuticals….
May 1, 2024
AFT Licenses Maxigesic® IV in Brazil
We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…
April 24, 2024
AFT, Massey Ventures, Gilles McIndoe to develop scar treatment
AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….